Assessing barriers to genetic and tumor genome sequence testing in patients with metastatic stage IV breast cancer at an academic and public hospital in Georgia.
245 Background: Genetic testing and tumor genome sequencing are essential in the management of metastatic stage IV breast cancer, enabling identification of actionable mutations that guide targeted therapy and improve outcomes. Despite guideline recommendations, uptake remains suboptimal, particularly in unders...